Featured Research

from universities, journals, and other organizations

Medications to prevent clots not reaching some patients

June 14, 2013
Johns Hopkins Medicine
Researchers report that hospitalized patients do not receive more than one in 10 doses of doctor-ordered blood thinners prescribed to prevent potentially lethal or disabling blood clots, a decision they say may be fueled by misguided concern by patients and their caregivers.

Researchers at Johns Hopkins report that hospitalized patients do not receive more than one in 10 doses of doctor-ordered blood thinners prescribed to prevent potentially lethal or disabling blood clots, a decision they say may be fueled by misguided concern by patients and their caregivers.

Related Articles

Calling the rate of missed doses "unacceptably high," the researchers add that hospitalized patients are at a significantly greater risk of developing venous thromboembolism, or VTE, and that preventive blood thinners can prevent it a majority of the time.

"There appeared to be a lack of understanding about the risks and benefits of blood thinners among patients and medical staff, even though the research is clear that blood thinners are very effective at preventing blood clots," says Kenneth M. Shermock, Pharm.D., Ph.D., the director of the Center for Medication Quality and Outcomes at The Johns Hopkins Hospital, and leader of the study published in the journal PLOS ONE. "Blood clots and their resulting effects are the most common cause of avoidable death for hospitalized patients and we've got a medication that can prevent most of these events. But too many patients are not benefitting."

Shermock and his colleagues say their study found that 12 percent of ordered doses were not administered to patients, with the most commonly documented reason being patient or family-member refusal (59 percent). Patients were sometimes off the floor getting tests or in surgery when the doses are scheduled to be given.

Other research done by Shermock suggests that in some cases nursing staff may have implied to patients that blood thinners are optional. Shermock says it is important to understand the reasons behind this finding and provide more education emphasizing the proven benefits of blood thinners for hospitalized patients.

For the PLOS ONE study, Shermock and his colleagues analyzed more than 103,000 VTE prophylaxis doses of unfractionated heparin or enoxaparin ordered for more than 10,500 patients at The Johns Hopkins Hospital between Dec. 1, 2007 and June 30, 2008. Patients from 29 floors were included in the analysis: 11 medicine floors, nine surgery floors, four neurology floors and five intensive care units. They found that while 12 percent of the time ordered doses of blood thinner were not given to the patients, some floors of the hospital had much lower compliance rates.

The findings are similar to results previously reported from a Harvard study, but on a much larger scale. At Harvard, in 2012, the researchers went on to provide an individual information session with every patient to explain the value of the blood thinner shots, an intervention that was successful but costly, Shermock says. The value of his larger study, Shermock says, is that a clear pattern of where the problem is at its worst emerged. The worst compliance rates were found on medicine floors, most notably two of them where some 25 to 30 percent of doses were not administered. Education programs specifically targeted to medicine floors, he says, could yield good results at a fraction of the expense.

Shermock says that, overall, a majority of patients get most of their prescribed doses, which are given at eight-, 12- or 24-hour intervals. Nearly 60 percent of patients received all of their ordered doses. Roughly 20 percent of patients accounted for 80 percent of missed doses, with 20 percent of patients missing at least a quarter of their doses and 10 percent missing more than half of their doses, he says.

Focusing specifically on those patients who have missed doses could make a big impact, he says. The electronic medical record could be of help with that, showing in real time which patients have refused their medication and thus lead to the staging of an immediate intervention. "We want to be able to get to these patients before there is an adverse event," he says.

In addition to gaining unique insight on the nature of the problem, the Johns Hopkins team appears to be out in front in terms of solutions. Since learning about the data from the study, the Johns Hopkins multidisciplinary Venous Thromboembolism Prevention Collaborative has conducted studies looking at provider and patient factors associated with non-administered doses of VTE prophylaxis. The committee has also learned from nurses, for example, that some patients refused prophylaxis because of the pain and bruising associated with the shots, so a pilot program has been started to test a new method of injection that is less painful.

Meanwhile, a research team led by Elliott R. Haut, M.D., intends to continue this new line of research thanks to a three-year $1.5 million contract from the Patient-Centered Outcomes Research Institute (PCORI), an independent, nonprofit organization authorized by Congress to fund research that will provide patients, their caregivers and clinicians with the evidence-based information needed to make better-informed health care decisions. The contract, entitled "Preventing Venous Thromboembolism: Empowering Patients and Enabling Patient-Centered Care via Health Information Technology," will allow the group to more effectively target and intervene in instances where blood thinners are not being provided, and work with patients, nurses and other members of the health care team to come up with better ways to provide effective VTE prophylaxis.

Michael B. Streiff, M.D., the study's senior author and an associate professor of medicine and pathology in the Division of Hematology, says there remains some discussion about whether all patients on medical floors need prophylactic blood thinners, because some may be at very low risk of developing blood clots. That being said, Streiff points out that we do not yet have a well-validated tool to identify which patients do not need prophylaxis.

"The nurses may be exactly right that some of the patients don't need blood thinners," he says, "but more research is needed."

Other Johns Hopkins researchers involved in the study include Brandyn D. Lau, M.P.H.; Deborah B. Hobson, B.S.N.; Valerie S. Ganetsky, Pharm.D.; Peggy S. Kraus, Pharm.D.; Leigh E. Efird, Pharm.D.; Christoph U. Lehmann, M.D.; Brian L. Pinto, Pharm.D., M.B.A.; and Patricia A. Ross, Pharm.D.

Story Source:

The above story is based on materials provided by Johns Hopkins Medicine. Note: Materials may be edited for content and length.

Journal Reference:

  1. Kenneth M. Shermock, Brandyn D. Lau, Elliott R. Haut, Deborah B. Hobson, Valerie S. Ganetsky, Peggy S. Kraus, Leigh E. Efird, Christoph U. Lehmann, Brian L. Pinto, Patricia A. Ross, Michael B. Streiff. Patterns of Non-Administration of Ordered Doses of Venous Thromboembolism Prophylaxis: Implications for Novel Intervention Strategies. PLoS ONE, 2013; 8 (6): e66311 DOI: 10.1371/journal.pone.0066311

Cite This Page:

Johns Hopkins Medicine. "Medications to prevent clots not reaching some patients." ScienceDaily. ScienceDaily, 14 June 2013. <www.sciencedaily.com/releases/2013/06/130614230352.htm>.
Johns Hopkins Medicine. (2013, June 14). Medications to prevent clots not reaching some patients. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2013/06/130614230352.htm
Johns Hopkins Medicine. "Medications to prevent clots not reaching some patients." ScienceDaily. www.sciencedaily.com/releases/2013/06/130614230352.htm (accessed March 31, 2015).

Share This

More From ScienceDaily

More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News


Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile

Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins